SAT1 Antibody

What is SAT1 and why is it significant in research?

SAT1 (Spermidine/spermine N1-acetyltransferase 1) is the key regulatory enzyme in polyamine catabolism, catalyzing the acetylation of spermidine or spermine to generate N1-acetyl spermidine or N1-acetyl spermine, and N1,N12-diacetylspermine. The cellular level of SAT1 is normally extremely low but can be rapidly induced by various stimuli including polyamines themselves. SAT1 has gained significant research interest due to its involvement in cancer progression, particularly in triple-negative breast cancer, inflammation pathways, and ferroptosis mechanisms. The protein has a calculated molecular weight of 20 kDa and is typically observed at 15-25 kDa in experimental systems, making it readily detectable with appropriate antibodies . Researchers target SAT1 to understand its role in normal cellular functions and pathological conditions, making SAT1 antibodies crucial investigative tools.

What applications are SAT1 antibodies validated for?

SAT1 antibodies are validated for multiple experimental applications in research settings. Each application requires specific optimization parameters for successful detection of the target protein.

For optimal results, researchers should titrate each antibody for their specific experimental systems and sample types, as performance can vary between antibody products and application contexts.

What species reactivity do commercial SAT1 antibodies typically exhibit?

Commercial SAT1 antibodies demonstrate varied cross-reactivity profiles across species. When selecting an antibody for research with non-human models, it's essential to verify specific species reactivity claims from manufacturers.

Species reactivity is typically determined through sequence homology analysis and experimental validation. Researchers working with less common model organisms should carefully assess sequence conservation of their target species against validated reactivity profiles before antibody selection.

How should SAT1 antibodies be stored to maintain functionality?

Proper storage is critical for maintaining antibody functionality and extending shelf-life. For SAT1 antibodies, manufacturers generally recommend:

• Long-term storage at -20°C, where antibodies remain stable for approximately one year after shipment

• For frequent use, storage at 4°C is acceptable for some formulations

• Avoiding repeated freeze-thaw cycles to prevent protein degradation

• Some formulations indicate that aliquoting may be unnecessary for -20°C storage

Typical storage buffer composition includes PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Smaller sized preparations (20μl) may contain 0.1% BSA as a stabilizer . When assessing antibody stability, manufacturers utilize accelerated thermal degradation tests (37°C for 48h), with acceptable loss rates below 5% within the expiration date under appropriate storage conditions .

What controls should be included when validating SAT1 antibody specificity?

Rigorous validation of SAT1 antibody specificity requires a comprehensive control strategy:

Published studies frequently use SAT1 knockdown/knockout systems to validate antibody specificity, providing a stringent control for specificity testing . Additionally, comparing observed band sizes to the expected molecular weight range (15-25 kDa) provides further confirmation of specificity in Western blot applications.

How does SAT1 expression correlate with cancer progression?

SAT1 expression patterns show significant associations with cancer progression, particularly in triple-negative breast cancer (TNBC). Multiple lines of evidence demonstrate its potential role as both a biomarker and therapeutic target:

Functional studies reinforce these correlative findings, as SAT1 knockdown inhibits proliferation and migration of TNBC cells both in vitro and in vivo . These findings collectively establish SAT1 as a potential prognostic biomarker in TNBC and suggest its utility as a therapeutic target.

What are the molecular mechanisms through which SAT1 affects autophagy?

SAT1 exerts significant effects on cellular autophagy through a complex molecular mechanism:

• SAT1 protein in the cytoplasm directly binds to YBX1 (Y-box binding protein 1)

• This interaction sustains YBX1 protein stability via deubiquitylation mediated by the E3 ligase HERC5

• Stabilized YBX1 promotes methyl-5-cytosine (m5C) modification of mTOR mRNA

• The m5C modification of mTOR mRNA increases its stability, leading to enhanced mTOR expression

• Elevated mTOR activity potently suppresses autophagy pathways

This mechanism reveals how SAT1 functions beyond its canonical role in polyamine metabolism to influence fundamental cellular processes like autophagy. The SAT1-YBX1-mTOR axis provides potential intervention points for therapeutic modulation of autophagy, particularly in contexts where SAT1 is overexpressed, such as TNBC.

What challenges arise when using SAT1 antibodies in multiplex immunoassays?

Incorporating SAT1 antibodies into multiplex immunoassay formats presents several technical challenges:

• Antigen saturation effects: When using the same antibody for both capture and detection (single epitope immunoassay), epitope saturation by the detection probe can compromise capture efficiency and reduce assay sensitivity

• Optimization complexity: Multiple parameters require simultaneous optimization, including:

  • Probe concentration

  • Antibody-to-label ratio

  • Contact time between probe and analyte before reaching capture antibodies

  • Positioning of capture regions along assay strips

• Hook effect management: This phenomenon causes signal decline at high analyte concentrations, requiring careful assay design to maintain accurate quantification across a wide dynamic range

• Cross-reactivity mitigation: In multiplex formats detecting multiple targets simultaneously, cross-reactivity between antibodies must be minimized through careful antibody pair selection

Research utilizing Design of Experiments (DoE) approaches has identified optimal strategies for addressing these challenges, with the 13-optimal DoE emerging as the most efficient approach for multiplex device design . These optimization strategies have successfully increased detection sensitivity for SAT-type antigens by a factor of two in lateral flow immunoassay formats.

How does SAT1 inhibition affect cellular pathways and pathological conditions?

SAT1 inhibition produces multifaceted effects on cellular pathways with potential therapeutic implications:

• Ferroptosis reduction: Inhibition of SAT1 alleviates ferroptosis in chondrocytes through downregulation of Alox15 (arachidonate 15-lipoxygenase) and activation of the Nrf2 antioxidant defense system

• Anti-inflammatory effects: SAT1 inhibition reduces inflammatory responses in chondrocytes, suggesting potential applications in inflammatory conditions

• Anti-tumor activity: SAT1 knockdown significantly inhibits proliferation and migration of TNBC cells both in vitro and in vivo, as demonstrated through CCK8 and clone formation assays

• Autophagy restoration: By disrupting the SAT1-YBX1-mTOR pathway, SAT1 inhibition potentially restores autophagy in contexts where it is pathologically suppressed

• Impact on protein stability networks: SAT1 inhibition affects YBX1 stability and its downstream targets, potentially modulating RNA modification patterns throughout the cell

These diverse effects highlight SAT1 as a multifunctional regulator at the intersection of several critical cellular pathways, making it an attractive target for therapeutic intervention in multiple disease contexts.

What transcription factors regulate SAT1 expression?

Research has identified JUN as a key transcriptional regulator of SAT1 expression:

• Correlation analysis: Among predicted transcription factors, JUN shows the strongest positive correlation with SAT1 expression

• Binding site identification: Four probable JUN binding sites in the SAT1 promoter were identified through JASPAR database analysis:

  • Site A: GGATCCTGAGTCACCCTGG

  • Site B: CCGCTATGACTAAG

  • Site C: AGGTAGTGAGTTATCTCAG

  • Site D: GTGTCATCATTAG

• Functional validation:

  • JUN knockdown significantly downregulates SAT1 at both mRNA and protein levels

  • Dual-luciferase reporter assays confirm reduced activity with JUN knockdown and enhanced activity with JUN overexpression

  • ChIP assays demonstrate direct binding of JUN to all four sites in the SAT1 promoter sequence

• Site-specific importance: Deletion mutant analysis revealed that "site C" plays the dominant role in JUN-mediated transcriptional activation of SAT1

This detailed understanding of SAT1's transcriptional regulation provides insights into potential upstream therapeutic targets that could modulate SAT1 expression in pathological conditions where it is overexpressed.

What are the optimal protocols for using SAT1 antibodies in Western blotting?

Successful Western blotting with SAT1 antibodies requires optimization of multiple parameters:

HEK-293 cells have been successfully used as positive controls for SAT1 Western blotting . When optimizing a new antibody, performing a dilution series across multiple cell or tissue types can help identify optimal conditions for specific experimental systems.

How should researchers optimize SAT1 antibody protocols for immunohistochemistry?

Effective IHC with SAT1 antibodies requires systematic optimization:

• Sample preparation:

  • Fixation method impacts epitope accessibility

  • Paraffin-embedded tissues typically require antigen retrieval

• Antigen retrieval:

  • TE buffer pH 9.0 is recommended for some SAT1 antibodies

  • Citrate buffer pH 6.0 provides an alternative retrieval option

  • Temperature and duration require optimization

• Antibody dilution optimization:

  • Start with manufacturer-recommended range (1:50-1:500) or 5-20μg/mL

  • Perform serial dilutions to identify optimal concentration

  • Balance specific staining intensity against background

• Incubation conditions:

  • Overnight incubation at 4°C often provides optimal sensitivity

  • Room temperature incubation may increase background

• Detection system selection:

  • Must be compatible with host species (typically rabbit IgG for SAT1 antibodies)

  • Amplification systems enhance sensitivity for low-abundance targets

• Control tissues:

  • Mouse brain tissue has been validated as a positive control for SAT1 IHC

  • Include negative controls (primary antibody omission, isotype control)

• Counterstaining optimization:

  • Adjust hematoxylin intensity to visualize tissue architecture without obscuring specific staining

For tissues with expected low SAT1 expression, signal amplification systems may be necessary to detect endogenous levels of the protein.

What strategies help troubleshoot weak or non-specific staining with SAT1 antibodies?

Resolving common issues with SAT1 antibody staining requires systematic troubleshooting:

For weak or absent staining:

• Increase antibody concentration within the recommended range (e.g., 1:50 instead of 1:500 for IHC)

• Optimize antigen retrieval (TE buffer pH 9.0 is specifically recommended for some SAT1 antibodies)

• Extend primary antibody incubation time (overnight at 4°C)

• Implement signal amplification systems

• Verify antibody storage conditions and avoid repeated freeze-thaw cycles

• Confirm target expression in your sample (use positive control tissues like mouse brain)

• Test alternative antibody clones targeting different epitopes

For high background or non-specific staining:

• Decrease antibody concentration

• Optimize blocking (increase duration, try alternative blocking reagents)

• Increase wash duration and frequency

• Pre-absorb antibody with immunizing peptide to confirm specificity

• Use more stringent washing buffers (increase detergent concentration)

• Filter antibody solution before use to remove aggregates

• Implement additional blocking steps (avidin/biotin block for biotin-based detection systems)

The observation that SAT1 antibodies typically detect proteins in the 15-25 kDa range provides a crucial checkpoint for specificity in Western blot applications.

What considerations apply when using SAT1 antibodies in ELISA-based detection?

ELISA-based detection of SAT1 requires attention to several technical considerations:

• Format selection:

  • Direct ELISA: Simplest format but potentially lower sensitivity

  • Sandwich ELISA: Higher sensitivity but requires antibodies targeting distinct epitopes

  • Competitive ELISA: Useful for small molecules or limited epitope availability

• Antigen saturation challenges:

  • Using the same antibody for capture and detection can create saturation issues

  • Hook effects can occur at high analyte concentrations where signal paradoxically decreases

  • Requires careful titration of capture and detection antibody concentrations

• Antibody pairs optimization:

  • For sandwich formats, antibodies must recognize non-overlapping epitopes

  • Test multiple antibody combinations when developing new assays

  • Consider using monoclonal-polyclonal pairs for optimal performance

• Sample considerations:

  • Matrix effects from different sample types require validation

  • Dilution series helps identify optimal sample concentration range

  • Include appropriate calibration standards in each assay

• Validation parameters:

  • Establish limits of detection and quantification

  • Determine intra- and inter-assay variability

  • Verify linearity across the relevant concentration range

  • Test for cross-reactivity with similar proteins

When developing ELISA systems for SAT1, Design of Experiments (DoE) approaches can efficiently optimize multiple parameters simultaneously to achieve maximal sensitivity and specificity .

How do the molecular characteristics of SAT1 influence antibody selection and validation?

SAT1's molecular characteristics significantly impact antibody selection and validation strategies:

• Molecular weight considerations:

  • SAT1 has a calculated molecular weight of 20 kDa but is typically observed at 15-25 kDa in experimental systems

  • When validating antibodies, this size range serves as an important specificity check

  • Post-translational modifications may cause shifts in apparent molecular weight

• Epitope accessibility:

  • SAT1 is primarily localized in the cytoplasm , requiring appropriate sample preparation for optimal detection

  • For fixed samples, antigen retrieval conditions significantly impact epitope availability

  • TE buffer pH 9.0 is recommended for some SAT1 antibodies, though citrate buffer pH 6.0 is an alternative

• Sequence conservation:

  • SAT1 antibodies show reactivity with human, mouse, and rat samples due to sequence conservation

  • Some antibodies demonstrate broader cross-reactivity including porcine, bovine, and Xenopus samples

  • Zebrafish SAT1 shows approximately 86% sequence identity with validated species

• Immunogen design:

  • Commercial antibodies use different immunogens:

    • SAT1 fusion protein Ag1154

    • Synthetic peptide from C-terminal region (residues 100-171)

    • Recombinant protein fragments (PrEST Antigen SAT1)

  • Immunogen selection influences epitope recognition and cross-reactivity profiles

Understanding these characteristics enables researchers to select appropriate antibodies for specific applications and experimental systems while implementing appropriate validation strategies.

How do researchers use SAT1 antibodies to investigate cancer biology?

SAT1 antibodies are crucial tools in cancer research, particularly for triple-negative breast cancer (TNBC) studies:

• Expression profiling:

  • Western blotting with SAT1 antibodies revealed significantly higher expression in TNBC compared to other breast cancer subtypes

  • Immunohistochemistry on tissue microarrays from 100 TNBC patients demonstrated that elevated SAT1 correlates with poor prognosis

• Cellular mechanism studies:

  • SAT1 antibodies enabled researchers to discover its direct binding with YBX1, revealing a previously unknown regulatory mechanism in cancer

  • Co-immunoprecipitation experiments using SAT1 antibodies identified protein interaction partners involved in mTOR pathway regulation

• Functional analyses:

  • Following SAT1 knockdown, antibody-based detection confirmed reduced protein levels in experimental systems, validating intervention efficacy

  • Western blotting tracked changes in SAT1 expression across multiple TNBC cell lines, identifying optimal models for functional studies

• Therapeutic targeting validation:

  • SAT1 antibodies monitor protein level changes in response to potential therapeutic interventions

  • Immunodetection confirms target engagement in drug development pipelines

• Prognostic biomarker development:

  • IHC staining with SAT1 antibodies enables stratification of patient samples for correlation with clinical outcomes

  • Quantitative analysis of staining intensity provides data for Kaplan-Meier survival analyses

These applications demonstrate how SAT1 antibodies serve as indispensable tools for investigating SAT1's role in cancer biology and developing potential therapeutic strategies.

What role does SAT1 play in ferroptosis and how do antibodies facilitate this research?

SAT1 has emerged as an important regulator of ferroptosis, with antibodies enabling key discoveries in this field:

• Pathway identification:

  • Western blotting with SAT1 antibodies revealed that SAT1 inhibition alleviates chondrocyte ferroptosis

  • Immunodetection demonstrated that this protective effect operates through downregulation of Alox15 and activation of the Nrf2 system

• Mechanism elucidation:

  • Protein-level analysis using SAT1 antibodies helps track changes during ferroptosis induction and inhibition

  • Co-immunoprecipitation with SAT1 antibodies can identify novel protein interactions in ferroptotic pathways

  • Subcellular localization studies using immunofluorescence track SAT1 redistribution during ferroptosis

• Therapeutic targeting:

  • SAT1 antibodies monitor protein levels following experimental manipulation of ferroptosis pathways

  • Western blot analysis confirms efficacy of SAT1-targeting interventions designed to modulate ferroptosis

  • Immunodetection validates knockdown or overexpression models used in ferroptosis research

• Cross-pathway interactions:

  • Antibody-based detection reveals connections between ferroptosis and inflammation pathways

  • Multiplex immunostaining with SAT1 and other pathway markers (Alox15, Nrf2) visualizes pathway relationships

These applications demonstrate how SAT1 antibodies contribute to our understanding of ferroptosis regulation and identify potential therapeutic approaches for conditions involving dysregulated ferroptosis.

How are SAT1 antibodies employed in studying its transcriptional regulation?

SAT1 antibodies have been instrumental in elucidating the transcriptional regulation of SAT1, particularly by the transcription factor JUN:

• Expression correlation studies:

  • Western blotting with SAT1 antibodies validated computational predictions of positive correlation between JUN and SAT1 expression

  • Protein-level detection confirmed that JUN knockdown significantly downregulates SAT1

• Chromatin immunoprecipitation (ChIP) assays:

  • While not using SAT1 antibodies directly, ChIP assays with JUN antibodies confirmed direct binding to the SAT1 promoter at four predicted sites

  • These findings were correlated with SAT1 protein levels detected using SAT1 antibodies

• Transcriptional regulation validation:

  • Following dual-luciferase reporter assays with SAT1 promoter constructs, SAT1 antibodies confirmed protein-level changes

  • Western blotting demonstrated that site C (AGGTAGTGAGTTATCTCAG) in the promoter plays the dominant role in JUN-mediated activation of SAT1

• Mutation analysis:

  • SAT1 antibodies helped validate the functional consequences of promoter deletion mutants

  • Protein detection confirmed the effects of disrupting specific binding sites on SAT1 expression

This research has established JUN as a key transcriptional regulator of SAT1, providing insights into upstream modulators that could be targeted to control SAT1 expression in pathological conditions.

What emerging applications of SAT1 antibodies are being developed for diagnostic purposes?

While primarily research tools, SAT1 antibodies show potential for diagnostic applications:

• Cancer biomarker development:

  • IHC staining with SAT1 antibodies could potentially stratify TNBC patients for prognostic evaluation

  • The correlation between SAT1 expression and poor patient outcomes suggests utility as a prognostic biomarker

  • Tissue microarray studies with 100 TNBC patients demonstrated that elevated SAT1 adversely affected survival outcomes

• Multiplex diagnostic platforms:

  • Research on multiplex lateral flow immunoassays (LFIAs) incorporating SAT serotype detection demonstrates the feasibility of SAT1-based diagnostics

  • Design of Experiments (DoE) approaches have optimized such assays, reaching visual detection limits of approximately 10^3.7 TCID/mL

  • Positioning optimization of capture regions significantly influences detectability in lateral flow formats

• Biofluid-based detection:

  • Antibody-based detection of SAT1 in biological fluids could potentially serve as minimally invasive biomarkers

  • ELISA formats optimized for different sample matrices would be required for such applications

• Companion diagnostics:

  • As therapeutic approaches targeting SAT1 develop, antibody-based detection could identify patients likely to respond to such interventions

  • Quantitative assessment of SAT1 levels might predict therapeutic efficacy

While most applications remain in research stages, the prognostic significance of SAT1 in cancer and its involvement in multiple pathological processes suggest potential future diagnostic applications pending further clinical validation.

How do SAT1 antibodies contribute to understanding SAT1's role in normal versus pathological conditions?

SAT1 antibodies enable comparative analysis between normal and pathological states:

• Expression level comparison:

  • Western blotting with SAT1 antibodies revealed significantly higher expression in TNBC tumors compared to adjacent normal tissues

  • Multiple datasets (GSE38959, GSE45827, GSE65194) confirmed this upregulation at the mRNA level, which was validated at the protein level using SAT1 antibodies

• Cellular localization studies:

  • Immunofluorescence with SAT1 antibodies confirms its primarily cytoplasmic localization

  • Alterations in subcellular distribution between normal and pathological states can be monitored

• Protein interaction networks:

  • Immunoprecipitation with SAT1 antibodies identified differential protein interactions in disease states

  • The SAT1-YBX1 interaction was discovered through such approaches, revealing a pathological mechanism in cancer

• Response to stimuli:

  • While normally expressed at low levels, SAT1 can be rapidly induced by various stimuli

  • Antibody-based detection tracks these dynamic changes across different physiological and pathological conditions

• Intervention studies:

  • SAT1 antibodies monitor protein levels following experimental interventions

  • Western blotting confirmed that SAT1 knockdown inhibits TNBC cell proliferation and migration

  • Similar approaches demonstrated that SAT1 inhibition alleviates chondrocyte ferroptosis and inflammation

These applications highlight how SAT1 antibodies contribute to understanding the contextual differences in SAT1 function between normal cellular processes and pathological states, informing potential therapeutic strategies.